Giredestrant Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Giredestrant comprises 20 peer-reviewed publications across 15 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Endometrial Neoplasms, and Breast Neoplasms. Most recent publication: Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study., J Clin Oncol, 2024.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.Martín M, Lim E, Chavez-MacGregor M, et al. · J Clin Oncol · 2024
- UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.Malhi V, Nowicka M, Chen YC, et al. · Cancer Chemother Pharmacol · 2024
- heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.Kuemmel S, Harper-Wynne C, Park YH, et al. · BMC Cancer · 2024
- Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.Hurvitz SA, Bardia A, Quiroga V, et al. · Lancet Oncol · 2023
- Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.Westin SN, Sill MW, Coleman RL, et al. · Gynecol Oncol · 2019
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Rosenberg JE, Hoffman-Censits J, Powles T, et al. · Lancet · 2016
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.Rini BI, Powles T, Atkins MB, et al. · Lancet · 2019
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.Le DT, Uram JN, Wang H, et al. · N Engl J Med · 2015
Publications by year
1976–2024: 20 publications.
1976
1
2011
1
2013
1
2014
1
2015
2
2016
1
2017
4
2018
2
2019
3
2023
1
2024
3
Publications by indication
Endometrial Neoplasms (16)
- Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
- Correction: A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
- Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Breast Neoplasms (4)
- Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
- UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
- heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
- Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Publications by journal
- J Clin Oncol3 papers
- BMC Cancer2 papers
- Gynecol Oncol2 papers
- Lancet2 papers
- Cancer Chemother Pharmacol1 paper
- Lancet Oncol1 paper
- J Natl Cancer Inst1 paper
- Oncotarget1 paper
- Eur J Cancer1 paper
- Cesk Otolaryngol1 paper
All Giredestrant publications (20)
2024 (3 papers)
- Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.Martín M, Lim E, Chavez-MacGregor M, et al. · J Clin Oncol · 2024 · Derived
- UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.Malhi V, Nowicka M, Chen YC, et al. · Cancer Chemother Pharmacol · 2024 · Derived
- heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.Kuemmel S, Harper-Wynne C, Park YH, et al. · BMC Cancer · 2024 · Derived
2023 (1 paper)
- Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.Hurvitz SA, Bardia A, Quiroga V, et al. · Lancet Oncol · 2023 · Derived
2019 (3 papers)
- Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.Westin SN, Sill MW, Coleman RL, et al. · Gynecol Oncol · 2019 · Background
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.Rini BI, Powles T, Atkins MB, et al. · Lancet · 2019 · Background
- Correction: A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.Cancer Discov · 2019 · Background
2018 (2 papers)
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.Jiao S, Xia W, Yamaguchi H, et al. · Clin Cancer Res · 2018 · Background
- Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.Gockley AA, Kolin DL, Awtrey CS, et al. · Gynecol Oncol · 2018 · Background
2017 (4 papers)
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.Strickland KC, Howitt BE, Shukla SA, et al. · Oncotarget · 2017 · Background
- RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.Schwartz LH, Seymour L, Litière S, et al. · Eur J Cancer · 2017 · Background
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.LoRusso PM · J Clin Oncol · 2017 · Background
- Immunotherapy and patients treated for cancer with microsatellite instability.Colle R, Cohen R, Cochereau D, et al. · Bull Cancer · 2017 · Background
2016 (1 paper)
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Rosenberg JE, Hoffman-Censits J, Powles T, et al. · Lancet · 2016 · Background
2015 (2 papers)
- Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.Xue G, Zippelius A, Wicki A, et al. · J Natl Cancer Inst · 2015 · Background
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.Le DT, Uram JN, Wang H, et al. · N Engl J Med · 2015 · Background
2014 (1 paper)
- Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.Miyasaka A, Oda K, Ikeda Y, et al. · BMC Cancer · 2014 · Background
2013 (1 paper)
- Integrated genomic characterization of endometrial carcinoma.Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. · Nature · 2013 · Background
2011 (1 paper)
- Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.Aghajanian C, Sill MW, Darcy KM, et al. · J Clin Oncol · 2011 · Background
1976 (1 paper)
- [Extraction of peripherally located bronchial foreign bodies using a x-ray picture amplifier with a television loop].Rous J, Rems J, Cermák Z, et al. · Cesk Otolaryngol · 1976 · Background
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 02 Jun 2026 17:10:17 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).